Curated News
By: NewsRamp Editorial Staff
May 06, 2025
Study Links Pregnancy-Specific Genes to Poorer Lung Cancer Outcomes in Women
TLDR
- Women with lung cancer may have poorer outcomes due to pregnancy-specific genes, creating opportunities for immune therapy companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI).
- Study at Memorial Sloan Kettering (MSK) Cancer Center reveals lung cancer hijacks genes linked to fetal growth to evade the immune system, impacting patient outcomes.
- Understanding how genes affect immune response in lung cancer can lead to the development of effective immune therapies, potentially improving outcomes for patients in the future.
- Research suggests that genes involved in fetal growth can play a role in lung cancer progression, offering new insights into cancer development and treatment strategies.
Impact - Why it Matters
This news sheds light on how lung cancer manipulates genes to escape immune surveillance, potentially paving the way for innovative immune therapies. Understanding these mechanisms can lead to improved treatment strategies and outcomes for patients battling cancer.
Summary
A recent study at Memorial Sloan Kettering Cancer Center reveals that lung cancer utilizes genes related to fetal growth to evade the immune system, leading to poorer outcomes in affected women. Companies like Calidi Biotherapeutics Inc. are exploring immune therapies based on this discovery to empower patients against cancer.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Study Links Pregnancy-Specific Genes to Poorer Lung Cancer Outcomes in Women
